TokenPost topic

BGB-B2033

1 TokenPost story is tagged BGB-B2033. The newest appear first.

Latest BGB-B2033 stories

• BeOne Reports 36% Response Rate for Liver Cancer Drug in Phase 1

  The result came from 25 evaluable patients given 450 milligrams every three weeks; BeOne plans larger trials by the end of 2026.

  Oct 24, 2026, 1:10 PM EDT · Business